Cagrilintide

CAS #: 1415456-99-3

Molecular Formula: C₁₉₄H₃₁₂N₅₄O₅₉

Molecular Weight: approx. 4,309.80 g/mol

Cagrilintide is a long-acting amylin analog designed to mimic the hormone amylin, which is co-secreted with insulin by pancreatic beta cells. Amylin plays a key role in appetite regulation, gastric emptying, and postprandial glucose control. Cagrilintide is engineered for extended activity, allowing once-weekly dosing and sustained appetite suppression. It is being developed both as a monotherapy and in combination with GLP-1 receptor agonists (such as semaglutide) for enhanced weight management.

Potent Appetite Suppression: Activates amylin receptors in the brain, increasing satiety and reducing overall caloric intake.

Delayed Gastric Emptying: Slows the rate at which food leaves the stomach, leading to improved post-meal fullness and more stable blood glucose levels.

Synergistic With GLP-1 Agonists: When combined with GLP-1 receptor agonists, demonstrates greater weight loss than either mechanism alone due to complementary pathways of appetite control.

Improved Postprandial Glucose Control: Helps blunt post-meal glucose spikes by regulating gastric emptying and glucagon secretion.

Sustained Weekly Activity: Structural modifications extend half-life, allowing once-weekly administration for consistent metabolic effects.

By targeting the amylin pathway — distinct from GLP-1 and GIP — cagrilintide adds an additional layer of appetite and metabolic regulation, making it a valuable adjunct in advanced weight management strategies.

*Shipping only available in the continental U.S.*

All products on this site are for research and development use only.